Selection of macrophage-resistant progressor tumor variants by the normal host. Requirement for concomitant T cell-mediated immunity (original) (raw)

Abstract

The ultraviolet radiation-induced fibrosarcoma 1591 is generally rejected by normal syngeneic mice, but occasionally the tumor succeeds in growing progressively. Analysis of these progressively growing tumors has regularly demonstrated the development of tumor variants that have acquired a heritable progressive growth potential. We have analyzed the phenotypic changes of these variants to determine which kind of selection pressure had occurred during the evolution of the variants, thus giving insight into the relative importance and hierarchy of the different immune defense mechanisms that may be operating in normal individuals as a defense against neoplastic cells. We discovered that all of the host-selected progressor variants had lost not only a strong T cell-recognized and tumor-specific antigen, but also their high sensitivity to cytotoxic macrophages. No selection for macrophage-resistance or loss of the tumor antigen was observed in 1591 tumors reisolated from idiotypically-suppressed mice or from other mice lacking tumor-specific T cell immunity. Analysis of other tumor variants selected in vitro showed that 1591 tumor cells have the potential to lose sensitivity to tumoricidal macrophages without losing the T cell-recognized tumor antigen. Thus the data suggest that T cells and macrophages act together to suppress the outgrowth of potentially malignant cells in vivo.

Full Text

The Full Text of this article is available as a PDF (1.1 MB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adams D. O., Marino P. A. Evidence for a multistep mechanism of cytolysis by BCG-activated macrophages: the interrelationship between the capacity for cytolysis, target binding, and secretion of cytolytic factor. J Immunol. 1981 Mar;126(3):981–987. [PubMed] [Google Scholar]
  2. Adams D. O., Snyderman R. Do macrophages destroy nascent tumors? J Natl Cancer Inst. 1979 Jun;62(6):1341–1345. [PubMed] [Google Scholar]
  3. Berendt M. J., North R. J., Kirstein D. P. The immunological basis of endotoxin-induced tumor regression. Requirement for a pre-existing state of concomitant anti-tumor immunity. J Exp Med. 1978 Dec 1;148(6):1560–1569. doi: 10.1084/jem.148.6.1560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Burton R. C., Winn H. J. Studies on natural killer (NK) cells. I. NK cell specific antibodies in CE anti-CBA serum. J Immunol. 1981 May;126(5):1985–1989. [PubMed] [Google Scholar]
  5. Currie G. A. Activated macrophages kill tumour cells by releasing arginase. Nature. 1978 Jun 29;273(5665):758–759. doi: 10.1038/273758a0. [DOI] [PubMed] [Google Scholar]
  6. Fisher M. S., Kripke M. L. Systemic alteration induced in mice by ultraviolet light irradiation and its relationship to ultraviolet carcinogenesis. Proc Natl Acad Sci U S A. 1977 Apr;74(4):1688–1692. doi: 10.1073/pnas.74.4.1688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Flood P. M., Kripke M. L., Rowley D. A., Schreiber H. Suppression of tumor rejection by autologous anti-idiotypic immunity. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2209–2213. doi: 10.1073/pnas.77.4.2209. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Flood P. M., Urban J. L., Kripke M. L., Schreiber H. Loss of tumor-specific and idiotype-specific immunity with age. J Exp Med. 1981 Aug 1;154(2):275–290. doi: 10.1084/jem.154.2.275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Glasebrook A. L., Fitch F. W. Alloreactive cloned T cell lines. I. Interactions between cloned amplifier and cytolytic T cell lines. J Exp Med. 1980 Apr 1;151(4):876–895. doi: 10.1084/jem.151.4.876. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gray J. D., Brooks C. G., Baldwin R. W. Detection of either rapidly cytolytic macrophages or NK cells in "activated" peritoneal exudates depends on the method of analysis and the target cell type. Immunology. 1981 Apr;42(4):561–568. [PMC free article] [PubMed] [Google Scholar]
  11. Hamilton T. A., Fishman M. Characterization of the recognition of target cells sensitive or resistant to cytolysis by activated rat peritoneal macrophages. J Immunol. 1981 Oct;127(4):1702–1706. [PubMed] [Google Scholar]
  12. Hibbs J. B., Jr, Lambert L. H., Jr, Remington J. S. Control of carcinogenesis: a possible role for the activated macrophage. Science. 1972 Sep 15;177(4053):998–1000. doi: 10.1126/science.177.4053.998. [DOI] [PubMed] [Google Scholar]
  13. Kripke M. L. Latency, histology, and antigenicity of tumors induced by ultraviolet light in three inbred mouse strains. Cancer Res. 1977 May;37(5):1395–1400. [PubMed] [Google Scholar]
  14. Lill P. H., Fortner G. W. Identification and cytotoxic reactivity of inflammatory cells recovered from progressing or regressing syngeneic UV-induced murine tumors. J Immunol. 1978 Nov;121(5):1854–1860. [PubMed] [Google Scholar]
  15. Loveland B. E., McKenzie I. F. Which T cells cause graft rejection? Transplantation. 1982 Mar;33(3):217–221. doi: 10.1097/00007890-198203000-00001. [DOI] [PubMed] [Google Scholar]
  16. Mackaness G. B. The influence of immunologically committed lymphoid cells on macrophage activity in vivo. J Exp Med. 1969 May 1;129(5):973–992. doi: 10.1084/jem.129.5.973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Mantovani A. In vitro effects on tumor cells of macrophages isolated from an early-passage chemically-induced murine sarcoma and from its spontaneous metastases. Int J Cancer. 1981 Feb 15;27(2):221–228. doi: 10.1002/ijc.2910270215. [DOI] [PubMed] [Google Scholar]
  18. Meltzer M. S. Macrophage activation for tumor cytotoxicity: characterization of priming and trigger signals during lymphokine activation. J Immunol. 1981 Jul;127(1):179–183. [PubMed] [Google Scholar]
  19. Meltzer M. S. Tumoricidal responses in vitro of peritoneal macrophages from conventionally housed and germ-free nude mice. Cell Immunol. 1976 Mar 1;22(1):176–181. doi: 10.1016/0008-8749(76)90018-6. [DOI] [PubMed] [Google Scholar]
  20. Nathan C. F., Arrick B. A., Murray H. W., DeSantis N. M., Cohn Z. A. Tumor cell anti-oxidant defenses. Inhibition of the glutathione redox cycle enhances macrophage-mediated cytolysis. J Exp Med. 1981 Apr 1;153(4):766–782. doi: 10.1084/jem.153.4.766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Nathan C. F., Karnovsky M. L., David J. R. Alterations of macrophage functions by mediators from lymphocytes. J Exp Med. 1971 Jun 1;133(6):1356–1376. doi: 10.1084/jem.133.6.1356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Oldham R. K., Ortaldo J. R., Holden H. T., Herberman R. B. Cytotoxicity inhibition assay: cryopreservation and standardization: brief communication. J Natl Cancer Inst. 1977 Oct;59(4):1321–1323. doi: 10.1093/jnci/59.4.1321. [DOI] [PubMed] [Google Scholar]
  23. Pace J. L., Russell S. W. Activation of mouse macrophages for tumor cell killing. I. Quantitative analysis of interactions between lymphokine and lipopolysaccharide. J Immunol. 1981 May;126(5):1863–1867. [PubMed] [Google Scholar]
  24. Roder J. C., Lohmann-Matthes M. L., Domzig W., Kiessling R., Haller O. A functional comparison of tumor cell killing by activated macrophages and natural killer cells. Eur J Immunol. 1979 Apr;9(4):283–288. doi: 10.1002/eji.1830090407. [DOI] [PubMed] [Google Scholar]
  25. Russell S. W., Gillespie G. Y. Nature, function and distribution of inflammatory cells in regressing and progressing Moloney sarcomas. J Reticuloendothel Soc. 1977 Aug;22(2):159–168. [PubMed] [Google Scholar]
  26. Talmadge J. E., Key M., Fidler I. J. Macrophage content of metastatic and nonmetastatic rodent neoplasms. J Immunol. 1981 Jun;126(6):2245–2248. [PubMed] [Google Scholar]
  27. Tonkonogy S. L., Winn H. J. A new alloantigenic system associated with the Mls locus in the mouse. J Immunol. 1976 Mar;116(3):835–841. [PubMed] [Google Scholar]
  28. Tucker R. W., Meltzer M. S., Sanford K. K. Susceptibility to killing by BCG-activated macrophages associated with "spontaneous" neoplastic transformation in culture. Int J Cancer. 1981;27(4):555–562. doi: 10.1002/ijc.2910270420. [DOI] [PubMed] [Google Scholar]
  29. Urban J. L., Burton R. C., Holland J. M., Kripke M. L., Schreiber H. Mechanisms of syngeneic tumor rejection. Susceptibility of host-selected progressor variants to various immunological effector cells. J Exp Med. 1982 Feb 1;155(2):557–573. doi: 10.1084/jem.155.2.557. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Urban J. L., Holland J. M., Kripke M. L., Schreiber H. Immunoselection of tumor cell variants by mice suppressed with ultraviolet radiation. J Exp Med. 1982 Oct 1;156(4):1025–1041. doi: 10.1084/jem.156.4.1025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Urban J. L. Macrophage-induced enhancement of endogenous tumor lysosome activity. Cancer Res. 1981 Jun;41(6):2221–2229. [PubMed] [Google Scholar]